Raymond James & Associates Buys 11,798 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Raymond James & Associates increased its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 17.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 81,235 shares of the company’s stock after buying an additional 11,798 shares during the quarter. Raymond James & Associates owned 0.07% of Vaxcyte worth $9,283,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of PCVX. Riverview Trust Co bought a new stake in Vaxcyte in the 3rd quarter valued at $27,000. Fifth Third Bancorp acquired a new stake in Vaxcyte in the second quarter valued at $35,000. Fidelis Capital Partners LLC acquired a new stake in Vaxcyte in the 1st quarter valued at about $37,000. Blue Trust Inc. boosted its stake in shares of Vaxcyte by 33.5% during the 3rd quarter. Blue Trust Inc. now owns 371 shares of the company’s stock worth $42,000 after acquiring an additional 93 shares during the period. Finally, J.Safra Asset Management Corp boosted its position in Vaxcyte by 649.4% during the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock worth $46,000 after purchasing an additional 526 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

PCVX has been the subject of a number of research analyst reports. Jefferies Financial Group boosted their price objective on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. BTIG Research upped their price objective on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Mizuho lifted their target price on Vaxcyte from $113.00 to $163.00 and gave the stock an “outperform” rating in a report on Tuesday, September 10th. Leerink Partners upped their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC raised their price target on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $147.50.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX opened at $105.56 on Wednesday. The stock has a market capitalization of $11.78 billion, a P/E ratio of -22.56 and a beta of 0.99. The stock’s fifty day moving average is $107.29 and its 200 day moving average is $85.10. Vaxcyte, Inc. has a 52 week low of $46.16 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter in the prior year, the business earned ($0.70) earnings per share. Equities research analysts forecast that Vaxcyte, Inc. will post -4.33 earnings per share for the current year.

Insider Activity at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total transaction of $1,184,700.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares in the company, valued at $37,822,574.24. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Vaxcyte news, CFO Andrew Guggenhime sold 42,000 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the transaction, the chief financial officer now owns 90,383 shares of the company’s stock, valued at $10,429,294.37. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $78.98, for a total value of $1,184,700.00. Following the completion of the transaction, the chief executive officer now directly owns 478,888 shares of the company’s stock, valued at $37,822,574.24. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 92,098 shares of company stock valued at $9,937,773 over the last three months. 3.10% of the stock is owned by insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.